Ferring appoints Jan Lundberg to Group Board
Saint-Prex, Switzerland – 18th February 2021 – Ferring Pharmaceuticals announced today that Jan Lundberg has been appointed to the Ferring Group Board, effective January 2021, as a non-executive director and Chairman of the Research and Development Committee, following the retirement of John Patterson.
“I would like to express my sincere appreciation for John’s commitment to Ferring, his considerable achievements, and his passion for science and innovation,” said Frederik Paulsen, Chairman of the Ferring Board of Directors. “I am delighted to welcome Jan to the Ferring Group Board and am confident that, with his strong scientific and medical background, Jan will provide significant value to Ferring and our patients as we move into our next phase of growth through innovation.”
Dr. Lundberg has 18 years’ leadership experience with global organisations such as AstraZeneca and Eli Lilly and supervised the discovery and development of more than 200 candidate drugs leading to 25 approved products across multiple therapeutic areas. He has also served on the boards of several biotechnology companies and on governmental committees in the EU and USA.
Dr. Lundberg holds M.D. and Ph.D. degrees, and before joining industry was Professor of Pharmacology at the Karolinska Institute in Sweden.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.